Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease

Switching to Etanercept in Intestinal Behcet’s Disease Complicated by Secondary Non-response to Anti-TNF-α Antibodies

The efficacy of anti-TNF-α antibodies including infliximab and adalimumab for refractory intestinal Behcet's disease has recently been demonstrated in a series of case reports. The efficacy of switching to a different kind of anti-TNF-α agent in the face of refractoriness to one kind of anti-TNFα agent, a common practice of proven efficacy in rheumatoid arthritis, has yet not been reported for ...

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases

The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet's disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conventional therapy were given ADA (160/80/40 mg every other week). Marked improvement (MI) was achi...

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

BACKGROUND/AIMS Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671). METHODS Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, foll...

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report

BACKGROUND Behcet's disease (BD) is a systemic inflammatory disease with the histopathological features of leukocytoclastic vasculitis that affects nearly all organs and systems. When it involves the intestine, it is called entero-Behcet's disease (entero-BD). CASE PRESENTATION Here we described a 23-year-old man with entero-BD refractory to conventional therapies who responded well to the co...

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?